| Date | Title | Description |
| 05.06.2025 | A New Dawn in South Korea: Lee Jae-myung's Presidential Victory and Its Implications | On June 3, 2025, South Korea witnessed a seismic shift in its political landscape. Lee Jae-myung, the outspoken leader of the Democratic Party, emerged victorious in a presidential election that reflected deep public discontent with the pre... |
| 03.06.2025 | Revolutionizing Clinical Trials: The New Age of Protocol Optimization and eCOA Implementation | The world of clinical trials is undergoing a seismic shift. With the rise of technology, particularly artificial intelligence (AI), the landscape is transforming. Companies like Medidata are at the forefront, introducing innovative solution... |
| 03.06.2025 | The Rise of Agentic AI: Transforming Healthcare and Business Operations | In the world of technology, change is the only constant. The rise of agentic AI is a prime example. This new wave of artificial intelligence is not just about automation; it’s about creating intelligent systems that can operate independentl... |
| 02.06.2025 | J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025 | Significant anti-tumor responses and reduction of brain metastases observed
SEOUL, South Korea, June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially anno... |
| 02.06.2025 | ConcertAI Provides Intelligent Automation of ASCO Guidelines into its Generative and Agentic AI Precision Suite and CancerLinQ SmartLinQ Solutions | ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology (ASCO) Guidelines through the... |
| 02.06.2025 | Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience | New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials
SINGAPORE, June 2, 2025 /PRNewswire/ -- Medidata, a Dassault Systèmes brand and leadin... |
| 30.05.2025 | Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs | Dr. Shah, Dr. Yao, Dr. Advani to present at ASCO's 2025 annual meeting.
Experts to share findings at American Society of Clinical Oncology annual meeting in Chicago
BUFFALO, N.Y., May 30, 2025 /PRNewswire-PRWeb/ -- In talks at the annual me... |
| 29.05.2025 | Revolutionizing Cancer Care: The Impact of AI and Innovative Therapies | In the battle against cancer, innovation is the weapon of choice. Recent breakthroughs in technology and treatment are changing the landscape of oncology. Two significant advancements stand out: the AION TempShield, an AI-powered wearable t... |
| 28.05.2025 | AI-Powered Wearable Cuts Cancer Deaths by 90 Percent Redefines Infection Detection in Chemotherapy | Findings Released in ASCO Abstract Validate Life-Saving Impact of AION TempShield’s Long-Term Temperature Tracking for Cancer Patients.
AION Biosystems today announced a major breakthrough in cancer care: TempShield™, an AI-powered wearable... |
| 23.05.2025 | Microsoft’s Healthcare Agent Orchestrator: A New Dawn for Cancer Care | In the world of healthcare, time is often the enemy. Every minute counts, especially when it comes to cancer treatment. Microsoft has stepped into this battlefield with its Healthcare Agent Orchestrator, a tool designed to revolutionize how... |
| 19.05.2025 | Microsoft Launches Healthcare Agent Orchestrator | What You Should Know:
– Microsoft announced the availability of its healthcare agent orchestrator in the Azure AI Foundry Agent Catalog.
– The platform features pre-configured AI agents, multi-agent orchestration, and open-source customizat... |
| 24.02.2025 | NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon C... | SAN FRANCISCO and SUZHOU, China, Feb. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 01.11.2024 | Akeso Biopharma: Pioneering New Frontiers in Cancer Treatment | In the realm of cancer treatment, hope often flickers like a candle in the dark. Akeso Biopharma, a rising star in the biopharmaceutical industry, is working to turn that flicker into a blazing light. With recent announcements of groundbrea... |
| 01.11.2024 | Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab | HONG KONG, Nov. 1, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, controlled, multicenter Phase III registration study... |
| 19.10.2024 | Bridging the Gap: Health Innovations and Advocacy for African American Communities | In a world where health disparities often mirror the lines of race and socioeconomic status, the upcoming Healthy Churches 2030 Virtual Conference stands as a beacon of hope. Scheduled for November 18-20, 2024, this event aims to empower Af... |
| 18.10.2024 | Dignitana Announces New CPT® Category I Codes from the American Medical Association for Mechanical Scalp Cooling | Dignitana Announces New CPT® Category I Codes from the American Medical Association for Mechanical Scalp Cooling
Fri, Oct 18, 2024 16:57 CET Report this content
Dignitana announces that three CPT® Category I codes for mechanical scalp cooli... |
| 08.10.2024 | Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer | SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 19.09.2024 | A New Dawn in Kidney Cancer Treatment: Roswell Park's Breakthrough Regimen | In the realm of cancer treatment, hope often flickers like a candle in the dark. But recent findings from Roswell Park Comprehensive Cancer Center have ignited a brighter flame for patients battling metastatic kidney cancer. At the European... |
| 15.09.2024 | Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer | Roswell Park's Saby George, MD, presented study findings highlighting a treatment combination shown to extend survival in patients with advanced kidney cancer.
During the European Society for Medical Oncology (ESMO) Congress, Saby George, M... |
| 29.08.2024 | Mabwell's Bold Step: A New Hope for Urothelial Carcinoma | In the bustling heart of Shanghai, Mabwell is making waves. The biopharmaceutical company recently received the green light from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to kick off a Phase... |
| 26.08.2024 | Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor | SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administ... |
| 08.08.2024 | T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors | Summary
T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer.
MT027, the pro... |
| 15.07.2024 | Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC | SHANGHAI, July 15, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been approved by the NMPA to enter Phase... |
| 12.06.2024 | 2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations | Introduction: ADC Drug Breakthrough Targets TF in Pancreatic Cancer
CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 31 to June 4, shone a spotlight on MRG... |
| 11.06.2024 | Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE | SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 07.06.2024 | Innovative Cancer Treatment LBL-024 Shows Promise in Phase II Results | The groundbreaking cancer research presented at the 2024 ASCO Annual Meeting showcased Leads Biolabs' innovative cancer treatment, LBL-024. This bispecific antibody has shown outstanding results in phase II trials, particularly in patients ... |
| 07.06.2024 | Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024 | JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened from May 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studie... |
| 05.06.2024 | Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy | SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluat... |
| 05.06.2024 | GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024 | YONGIN, South Korea, June 5, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, presented new data from its AI-based liquid biopsy platform for non-invasive colorectal cancer (CRC) detection at the 2024 American Soci... |
| 03.06.2024 | Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting | SHANGHAI, June 3, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company, announced today that the preliminary Phase 1/2 clinical data of MHB088C (B7-H3 ADC) was presented at the 2024 American Soc... |
| 03.06.2024 | Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual M... | NANJING, China, June 3, 2024 /PRNewswire/ -- The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on May 31st, Showcasing groundbreaking cancer research from around the world. According to official information, o... |
| 03.06.2024 | Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting | Results from the phase I part of JSKN003-102 was reported at this ASCO Annual Meeting.
JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonst... |
| 03.06.2024 | Кто будет разрабатывать лекарства? | Появление новых лекарств — всегда ожидаемое событие. Несмотря на широкомасштабные исследования фармкомпаний эффективных средств по–прежнему не хватает. В среднем на разработку одного препарата уходит 10–15 лет и около 2,5 млрд долларов — эт... |
| 03.06.2024 | Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2024 | Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO | BEIJING and SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combinatio... |
| 02.06.2024 | Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual M... | NANJING, China, June 2, 2024 /PRNewswire/ -- The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on May 31st, Showcasing groundbreaking cancer research from around the world. According to official information, o... |
| 01.06.2024 | TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting | Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors
A 40% overall response rate (ORR) and 100% disease control rate (DCR) w... |
| 01.06.2024 | TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting | Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors
A 40% overall response rate (ORR) and 100% disease control rate (DCR) w... |
| 31.05.2024 | New Lung Cancer Drug Halts Disease Progression Longer Than Ever Before | By John Lopez
Published May 31, 2024 11:22AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
A groundbreaking development in lung cancer treatment has emerged with the first trial ... |
| 30.05.2024 | BioStock: BioInvent to present promising clinical data at ASCO and EHA | BioStock: BioInvent to present promising clinical data at ASCO and EHA
Thu, May 30, 2024 12:43 CET Report this content
In the coming weeks, BioInvent is set to present three significant data sets at the American Society for Clinical Oncolog... |
| 29.05.2024 | Mercy BioAnalytics Receives Breakthrough Device Designation for Ovarian Cancer Screening in Asymptomatic, Postmenopausal Women | WALTHAM, Mass., May 29, 2024 /PRNewswire/ -- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, has been granted Breakthrough Device Designation from the U.S. Food and Drug Ad... |
| 29.05.2024 | Canopy Announces Results of Three-Year ePRO Study to Be Presented at 2024 American Society of Clinical Oncology Meeting | Research Demonstrates Improved High-Risk Symptom Detection, Comparable Outcomes with ePRO Compared to Phone Triage
NEW YORK, May 29, 2024 /PRNewswire/ -- Canopy, the first Continuous Care Platform for oncology, today announced results from ... |
| 28.05.2024 | PreciseDx Announces Poster Presentation at The 2024 American Society of Clinical Oncology Annual Meeting | The poster presentation features findings from PreciseDx's collaboration with the Laboratory of Pathology, Dordrecht Albert Schweitzer Hospital in the Netherlands.
NEW YORK, May 28, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in on... |
| 24.05.2024 | ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates | SUZHOU, China and ROCKVILLE, Md., May 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 24.05.2024 | Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA.
Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway.
T... |
| 24.05.2024 | Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024 | SHANGHAI, May 24, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced latest clinical resea... |
| 24.05.2024 | Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA.
Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway.
T... |
| 24.05.2024 | Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting | SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple adva... |
| 24.05.2024 | CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website | CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development.
First-in-human study data show that CS5001 ... |
| 24.05.2024 | Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting | SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple adva... |
| 23.05.2024 | EBCI Partners with ASCO to Boost Patient Education, Access and Clinical Trial Participation | EBCI Partners with ASCO to Boost Patient Education, Access and Clinical Trial Participation REDMOND, WA, USA, May 23, 2024 /EINPresswire.com/ -- The End Brain Cancer Initiative (EBCI) engages directly with healthcare professionals and compa... |
| 23.05.2024 | Rutgers Cancer Institute and RWJBarnabas Health Set to Unveil Extensive, New Cancer Research Findings at 2024 ASCO Annual Meeting | 49 scheduled presentations will explore several types of cancer, as well as the next frontier of health equity
NEW BRUNSWICK, N.J., May 23, 2024 /PRNewswire/ -- Clinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health ... |
| 13.05.2024 | Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting | 16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers
TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas")... |
| 13.05.2024 | Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral Presentation and Two Posters. | NANJING, China, May 13, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024. As the largest and most academically prestigious international oncology c... |
| 10.05.2024 | Health | Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge | The FDA conditionally approved sotorasib but required Amgen to conduct a study comparing the labeled dosage of 960 mg with a dosage of 240 mg. The trial, published in November, showed that the 960-mg dose may have given patients a month mor... |
| 09.05.2024 | Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights | Pelareorep advancing to registration-enabling studies
Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer
Overall survival data from BRACELET-1 breast cancer study ... |
| 06.05.2024 | Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting | SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted in China (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment ... |
| 30.04.2024 | Lung Cancer Research Foundation Welcomes New Scientific Advisory Board Members | Foundation Expands its Research Reviewing Body to Meet Strategic Research Investment Objective
NEW YORK, April 30, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) has expanded its Scientific Advisory Board (SAB) by five new ... |
| 25.04.2024 | Antengene Announces One Oral and Three Poster Presentations at ASCO 2024 | Oral session：ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer
Three Poster presentations: Phase I/II studies for ATG-031 (anti-CD24 monoclonal antibody) and ATG-022 (Claudin 18.2 antibody-drug... |
| 24.04.2024 | Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting | Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference.
SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutica... |
| 19.04.2024 | GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer | SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical t... |
| 07.04.2024 | FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations | SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for p... |
| 02.04.2024 | Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States | Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States
Tue, Apr 02, 2024 10:57 CET Report this con... |
| 29.03.2024 | Jacobio Pharma Announces 2023 Annual Results | BEIJING, SHANGHAI and BOSTON, March 29, 2024 Jacobio/PRNewswire/ -- Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D ... |
| 21.03.2024 | Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved | SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit of... |
| 15.03.2024 | Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024 | JINAN, China, March 15, 2024 /PRNewswire/ -- On 8 March local time, during the 25th European Society of Gynecological Oncology (ESGO) Conference (ESGO 2024) in Spain, Qilu Pharmaceutical unveiled the Phase II clinical trial results for ipar... |
| 07.02.2024 | HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in ... |
| 07.06.2023 | SimcereZaiming showcases latest R&D progressed on its debut at ASCO， as 6 studies regarding 3 products published at ASCO | Bijoyesh Mookerjee，M.D., CMO of Simcere Zaiming（left 4）held pleasant conversation with visitors at Zaiming’s booth
Zaiming showcased the company’s innovative R&D pipeline at ASCO Booth
Simcere Zaiming, an innovative oncology-focused bio... |
| 30.05.2023 | Health
Health | These experts are seeing spikes in drug shortages. ‘I view this as a national health emergency’ | Shortages of essential drugs are threatening to become a crisis in the United States, health care providers say.
While cancer drugs have been most publicized recently, experts in pharmacy say they often find themselves scrambling to find co... |
| 17.05.2023 | Health
Health | Vaccine to fight cancer shows promise using mRNA technology | The same technology that was used to create Moderna’s COVID-19 vaccine is being targeted on melanoma, and the treatment is having positive effects, according to researchers at the Yale Cancer Center.
It’s another step in using the body’s im... |
| 12.09.2022 | The aftermath of childhood cancer: 2,000 days without Ana | A decade ago, on a bright Saturday morning in August, I took my 11-year-old daughter, Ana, to an emergency clinic. She had a terrible stomach ache. Something seemed wrong.
That morning, there was a stick bug on our car’s passenger door mirr... |
| 07.06.2022 | ASCO: Black Patients With Metastatic Breast Cancer Willing to Consider Clinical Trials | TUESDAY, June 7, 2022 (HealthDay News) -- Black patients with metastatic breast cancer (MBC) are willing to consider participating in clinical trials, according to a study presented at the annual meeting of the American Society of Clinical ... |
| 01.06.2022 | Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism | CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializa... |
| 28.05.2022 | Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting | BEIJING, SHANGHAI and BOSTON, May 28, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual m... |
| 26.05.2022 | Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor | Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor
Thu, May 26, 2022 23:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) to... |
| 26.05.2022 | Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer | Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer
Thu, May 26, 2022 23:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported e... |
| 26.05.2022 | Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC | Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC
Thu, May 26, 2022 23:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported updated interim resul... |
| 25.01.2022 | Deciphera Pharmaceuticals : Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session - Form 8-K | Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
- Efficacy Observed with QINLOCK® was Comparable to Sunitinib with a More Favorable Safe... |
| 25.01.2022 | Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session | Deciphera Pharmaceuticals, Inc. announced the presentation of results from the INTRIGUE Phase 3 study of QINLOCK (ripretinib) in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib at the American Society of... |
| 19.11.2021 | Lessons learned from 2020: Expanding virtual care beyond traditional telemedicine | The impact of the Covid-19 pandemic is shaping the future of healthcare in nearly every realm, from provider reimbursement, to in-person visit volume, to triage services. However, the pandemic has arguably had the largest effect on the adop... |
| 12.11.2021 | Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2021 [IFRS] | Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2021 [IFRS]
November 12, 2021
Company name : Otsuka Holdings Co., Ltd.
Stock exchange listing : Tokyo Stock Exchange
Code number : 4578
URL : https:... |
| 22.06.2021 | ASCO American Society of Clinical Oncology : Individuals with Cancer Must Be Included in COVID-19 Vaccine Trials | New ASCO-Friends Joint Position Statement Encourages Enrollment of Patients with Cancer in Vaccine Studies
For immediate release June 22, 2021
Contact
Rachel Martin
571-483-1383
Rachel.Martin@asco.org
ALEXANDRIA, Va. & Washington, DC - ... |
| 04.06.2021 | ASCO American Society of Clinical Oncology : Both Single and Dual Immunotherapy Regimens Offer Improved Overall Survival for Select Patients With Advanced Esophageal Cancer | Scroll Down to View the Presscast Presentation Recording
For immediate release June 3, 2021
Contact
Rachel Cagan
571-483-1684
mediateam@asco.org
ASCO Perspective
'Certain patients with advanced esophageal cancer, who currently have few trea... |
| 04.06.2021 | ASCO American Society of Clinical Oncology : Post-Surgery Immunotherapy Extends Disease-Free Survival for Select Patients With Kidney Cancer | Scroll Down to View the Presscast Presentation Recording
For immediate release June 3, 2021
Contact
Rachel Cagan
571-483-1684
mediateam@asco.org
ASCO Perspective
'Despite surgery, recurrence is common in clear-cell renal cell carcinoma, and... |
| 21.05.2021 | IMMUTEP LIMITED
Immutep : announces publication of TACTI-002 and INSIGHT-004 abstracts for ASCO 2021 Annual Meeting (Form 6-K) | Immutep announces publication of TACTI-002 and INSIGHT-004 abstracts
for ASCO 2021 Annual Meeting
SYDNEY, AUSTRALIA - 20 May 2021 -Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a biotechnology company developing nov... |
| 20.05.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology : Biotech Announces Release of Abstract for 0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting | FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating tech... |
| 20.05.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology : Biotech Announces Release of Abstract for 0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting (Form 8-K) | PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting
Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory check... |
| 20.05.2021 | IMMUTEP LIMITED
Immutep : Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting | SYDNEY, AUSTRALIA, May 20, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseas... |
| 19.05.2021 | Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology | Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology Wed, May 19, 2021 23:00 CET
STOCKHOLM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused... |
| 11.05.2021 | ACHILLES THERAPEUTICS PLC
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights | - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -
- Completed initial public offering of ADSs raising $175.5 mi... |
| 31.01.2021 | How Mount Sinai is using tech to support cancer patients amid the pandemic | Their goal? To enhance care for cancer patients.
Current Health provides a wearable device to patients, which continuously monitors their vital signs, said Chris McCann, co-founder and CEO of Current Health, in a phone interview. The data i... |
| 26.05.2020 | EPIC SCIENCES TO PRESENT MULTIPLE ABSTRACTS AT ASCO 2020 HIGHLIGHTING THE IMPORTANCE OF CTCs IN LIQUID BIOPSY | SAN DIEGO, Calif., May 26, 2020 – Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic Scien... |
| 01.11.2018 | Pricey precision medicine often financially toxic for cancer patients | When Kristen Kilmer was diagnosed with incurable breast cancer at age 38, her first thought was of her 8-year-old daughter. Kilmer lost her own mother as a teenager and was determined to get more time with her only child.
Kilmer searched fo... |
| 03.09.2018 | PBM practices harm care for cancer patients, oncology professional group says | Errors in filling prescriptions, alterations to treatment doses without consultation with oncology care providers, treatment delays from prior-authorization requirements, duplicate copays from incomplete dispensing and drug waste from incor... |
| 13.07.2018 | Don’t lock genomic data into silos | Genomic data must be shareable
But there’s a significant barrier and, sadly, it’s a familiar one.
The healthcare industry has struggled with interoperability and data sharing – or lack thereof – for decades. Critical patient information is ... |
| 12.07.2018 | US slower than Europe, emerging markets in liquid biopsy adoption | From left: Shoshannah Roth, Michael Nall, Rob Dumanois, Eugean Jiwanmall
One of the most cutting-edge trends in oncology diagnostics is liquid biopsy, which enables the use of a blood test to guide cancer treatment rather than having to ext... |
| 09.07.2018 | Biodesix acquires Seattle-based developer of blood-based lung nodule test | Results of the prospective clinical trial PANOPTIC showed that XL2 was 98 percent effective at distinguishing benign from malignant nodules.
In March, Biodesix announced a follow-on sale to increase the size of its offering of Series G shar... |
| 01.06.2018 | Fitango Health Unveils Oncology Precision Medicine App for Providers to Achieve Value-Based Goals | Fitango Health, a provider of integrated care management and patient engagement software, is announcing a transformative new solution, called Fitango Oncology. Fitango Health’s innovative application allows healthcare providers to achieve v... |
| 30.05.2018 | J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial | The CAR-T was originally developed by Nanjing, China-based Legend, under the development name LCAR-B38M. Janssen announced in December that it had paid Legend $350 million upfront for a worldwide licensing agreement for the therapy. The Chi... |
